SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
39.75
-0.20 (-0.50%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close39.95
Open39.93
Bid0.00 x 0
Ask0.00 x 0
Day's Range39.56 - 40.07
52 Week Range38.14 - 50.65
Volume1,050,845
Avg. Volume1,693,798
Market Cap99.995B
Beta0.83
PE Ratio (TTM)9.71
EPS (TTM)4.09
Earnings DateN/A
Forward Dividend & Yield1.64 (4.01%)
Ex-Dividend DateN/A
1y Target Est47.67
Trade prices are not sourced from all markets
  • Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
    Market Realist10 hours ago

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.

  • With deadline looming, Takeda nears agreement to buy Shire, says Bloomberg
    American City Business Journals21 hours ago

    With deadline looming, Takeda nears agreement to buy Shire, says Bloomberg

    The merger would create a company that would rival Sanofi Genzyme as the largest life sciences employer in Massachusetts.

  • Reuters23 hours ago

    UK bans Sanofi epilepsy drug without pregnancy prevention plan

    A Sanofi (SASY.PA) drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention programme. The move follows a scandal over the lack of information given to patients about the risks associated with valproate, which was first approved in France in 1967 and remains a widely used treatment for epilepsy. It is sold by Sanofi under the brand Depakine for epilepsy and Depakote and Depamide for bipolar disorders.

  • Sanofi (EPA:SAN): Immense Growth Potential?
    Simply Wall St.yesterday

    Sanofi (EPA:SAN): Immense Growth Potential?

    Sanofi’s (ENXTPA:SAN) latest earnings announcement in December 2017 showed that the business experienced a significant headwind with earnings declining by -13.74%. Today I want to provide a brief commentary onRead More...

  • GlobeNewswireyesterday

    Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

    Paris - 24th April 2018   -- Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011.

  • Motley Fool4 days ago

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Reuters6 days ago

    WHO recommends testing before use of Sanofi's dengue vaccine

    The World Health Organisation on Thursday said Sanofi's vaccine against dengue should only be used after testing individuals to assess whether they could have been exposed before to the infection. "We have now clear information that the vaccine needs to be dealt in a safer way by using it exclusively in people already infected," Alejandro Cravioto, Chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told journalists. After new analysis of data, Sanofi warned in November the vaccine could increase the risk of severe dengue in some cases in people who had not been previously exposed to the disease.

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks6 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Analysts’ Recommendations for Novartis on April 17
    Market Realist7 days ago

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • Novartis’s 1Q18 Estimates: Expectations for Sandoz
    Market Realist7 days ago

    Novartis’s 1Q18 Estimates: Expectations for Sandoz

    Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.

  • Reuters8 days ago

    Sanofi's CFO Contamine to retire later this year

    PARIS (Reuters) - Sanofi's (SASY.PA) executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, ...

  • Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
    Bloomberg8 days ago

    Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker

    Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.

  • Novartis’s Innovative Medicines Segment in 1Q18
    Market Realist8 days ago

    Novartis’s Innovative Medicines Segment in 1Q18

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.

  • The Wall Street Journal8 days ago

    [$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion

    The firm has presented a €1.9 billion ($2.35 billion) binding offer for the drugmaker.

  • In Pharma, If You Can't Join Them, Beat Them
    Bloomberg8 days ago

    In Pharma, If You Can't Join Them, Beat Them

    Advent is preparing to take on a drugmaker it tried and failed to buy.

  • Reuters8 days ago

    Bank trio expected to lead financing on Zentiva sale

    Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s (SASY.PA) European generics drugs arm Zentiva, banking sources said. Sanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.

  • Reuters8 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 billion

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • Reuters8 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 bln

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • Financial Times8 days ago

    [$$] Advent in exclusive talks to buy Sanofi generics business

    Private equity firm Advent has confirmed that it has entered into exclusive negotiations to buy Zentiva, Sanofi’s European generics business, for €1.91bn. A statement from the two firms on Tuesday said ...

  • The Wall Street Journal8 days ago

    [$$] Sanofi in Talks With Advent to Sell Zentiva

    Sanofi said it has entered exclusive talks to sell its European generic business Zentiva to Advent International for €1.92 billion.

  • Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech
    Bloomberg8 days ago

    Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech

    Sanofi plans to sell its European generic-drug unit to buyout firm Advent International Corp. for 1.9 billion euros ($2.4 billion) as part of a broader move by Chief Executive Officer Olivier Brandicourt ...

  • GlobeNewswire8 days ago

    Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi`s European generics business Advent to invest in Zentiva to ...

  • Upadacitinib Could Drive AbbVie’s Long-Term Growth
    Market Realist9 days ago

    Upadacitinib Could Drive AbbVie’s Long-Term Growth

    In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.

  • The Wall Street Journal9 days ago

    [$$] Charterhouse Portfolio Company Closes Sanofi Deal

    Cooper-Vemedia paid €158 million ($194.8 million) for 12 pharmaceutical brands.

  • Sanofi in talks to sell generics arm for $2.4 bln
    Reuters Videos8 days ago

    Sanofi in talks to sell generics arm for $2.4 bln

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion). Sonia Legg reports.